Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Novavax files for interim authorization of COVID-19 vaccine in Singapore

$Novavax (NVAX.US)$ announces its submission to the Singapore Health Sciences Authority (HSA) for interim authorization of its COVID-19 vaccine, NVX-CoV2373, under the Pandemic Special Access Route.
Shares down 1.4% premarket at $198.
The filing includes clinical data from two pivotal Phase 3 clinical trials, PREVENT-19 conducted in U.S. and Mexico; and U.K. trial including 15,000 participants.
Novavax recently received Emergency Use Authorization (EUA) for the vaccine in Philippines, and has filed for vaccine approval in South Korea.
Novavax' COVID-19 vaccine is packaged as a ready-to-use liquid formulation in a vial containing ten doses. The vaccination regimen calls for two 0.5 ml doses (5 microgram antigen and 50 microgram Matrix-M adjuvant) given intramuscularly 21 days apart. The vaccine is stored at 2°- 8° Celsius, enabling the use of existing vaccine supply and cold chain channels.
The EMA has also started evaluating Novavax's marketing application for its COVID-19 vaccine.
Novavax files for interim authorization of COVID-19 vaccine in Singapore
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
3
19
+0
7
Translate
Report
26K Views
Comment
Sign in to post a comment